Introduction
Numerous data are available which indicate that left ventricular hypertrophy (LVH), as a complication of hypertension, 1 is a major risk factor of life-threatening cardiovascular events. [2] [3] [4] To address this issue, several studies investigated the positive effect of anti-hypertensive therapy on LVH regression and provided evidence that lowering blood pressure (BP) is likely to induce a regression of LVH, in a first step with uncontrolled, open, non-randomised data 5, 6 obtained on small population size, then more recently through larger scale, controlled, randomised, blinded studies. [7] [8] [9] Furthermore, this decrease in LVH was associated with a reduced risk of cardiovascular morbidity and mortality events. [10] [11] [12] Additional studies are being carried out to test the hypothesis that the regression of LVH on anti-hypertensive treatment will lower the rate of morbid and fatal cardiovascular events. 13 LVH regression was observed with several anti-hypertensive drug hydrochlorothiazide and atenolol will be allowed for blood pressure control. Patients will be studied by twodimensional and M-mode echocardiography at baseline (central validation of LV hypertrophy), on randomisation day, and after 6 and 12 months randomised therapy. Blinded analysis of echocardiograms will be performed at a central laboratory, which will provide measurements of the LV mass index (LVMI), determined by Mmode readings according to Devereux formula and using the Penn convention. The primary end-point of the study will be the change in LVMI from baseline to 12 months. The study power is 90% to detect differences between groups from baseline of approximately 8 g/m 2 .
classes, such as diuretics, 8, 9, [14] [15] [16] ␤-blockers, 9, 14, 17, 18 angiotensin-converting enzyme (ACE) inhibitors 6, 9, 17, 19 or calcium channel blockers. 8, [20] [21] [22] It should be highlighted from these data that the greater reduction of LVH was obtained after a follow-up of 1 year 9,21 or even longer, 22 therefore far longer than the follow-up required to observe a lowering effect on BP.
Angiotensin-II receptor antagonists are a new class of anti-hypertensive agents currently under investigation 31 already evidenced as at least equal to ACE inhibitors, 24 calcium channel blockers or ␤-blockers. 25 Data which indicate that angiotension-II receptor antagonists induce LVH regression are still scarce and controversial. 26 However, recent evidence indicates that in spontaneously hypertensive rats, although an angiotensin-II receptor antagonist lowered BP to a comparable degree compared to an ACE inhibitor or calcium-channel blocker, it caused regression of LVH to a greater extent than the latter. 27 Irbesartan (SR 47436;BMS 186295) is a new anti-hypertensive agent [28] [29] [30] belonging to this class. [31] [32] [33] The aim of the present study is to ascertain the effect of irbesartan on LVH, versus a calcium channel blocker, felodipine. 34, 35 Felodipine was selected because it has been shown as effective in the regression of LVH. 22, 23 In addition, it offered the possibility of titration, in parallel with the doubleblind titration of irbesartan. 36 Finally, few studies are available comparing two anti-hypertensive agents with such different pharmacological properties.
Subjects and methods

Study design
The SILVER trial is designed to test the following hypothesis: administration of an irbesartan regimen once daily for 12 months will produce a greater reduction in LVH than a felodipine regimen administered once daily for 12 months in a patient population with hypertension, defined by seated diastolic BP (SeDBP) 95-115 mm Hg or seated systolic BP (SeSBP) 160-200 mm Hg, associated with LVH.
Objectives
The primary objective is a comparison of the change in left ventricular mass index (LVMI), measured by echocardiography, following 52 weeks of once daily therapy with either irbesartan regimen or felodipine regimen in patients with hypertension. The secondary objectives: (i) the changes in LVMI after 24 weeks of either therapy regimen, (ii) the changes in both SeDBP and SeSBP from baseline at 24 and 52 weeks, respectively, (iii) the safety and tolerability of either therapy regimen during 52 weeks of treatment, and (iv) the incidence of patients reporting oedema related to study drug.
Study outline
The study schematic plan is shown in Figure 1 . SILVER is a randomised, double-blind, double- dummy, parallel-group study, which will consist of a 3-week (optional 4-week) single-blind placebo lead-in period A (wash-out/qualification), followed by a 52-week randomised, double-blind period B. Blinded study medication will be electively titrated according to the return of BP to normal values (SeDBP Ͻ90 mm Hg or SeSBP Ͻ140 mm Hg). Echocardiograms will be recorded at baseline, on day of randomisation, and at 24 and 52 weeks of randomised therapy regimen. The study protocol was submitted and approved by all relevant ethical boards and committees from the various European countries participating to the trial.
Subjects
A total of 360 men and women of non-childbearing potential, aged Ͼ18 years will be randomised to either irbesartan or felodipine treatment regimens. Patients will be selected on the basis of increased echocardiographic LVMI, 116 g/m 2 in men and 104 g/m 2 in women. 3, 11, 37 Subjects will be screened according to a newly diagnosed hypertension or after washout from previous anti-hypertensive or vasodilator therapies. A screening echocardiogram will be performed by the investigating site and sent to the central echocardiography laboratory for quality control assessment and confirmation that the LVMI value meets the eligibility requirements of the study. The central echocardiography laboratory will provide the response to the investigating site within 5 working days starting from the receipt of the echocardiography video tape at the central laboratory.
Inclusion and exclusion criteria
To enter the screening phase, patients must have hypertension defined as SeDBP in the range 95-110 mm Hg (95-115 mm Hg for randomisation) or SeSBP in the range 160-200 mm Hg and provide written informed consent. BP measurement guidelines recommend to obtain both SeDBP and SeSBP from three replicate measurements performed at least after 1-min intervals. Except for the screening BP reading, all BP measurements will be made at trough, ie, 24 ± 3 h after the last dose of the study drug. SeDBP will be recorded at the cessation of phase V Korotkoff sounds. Among the main exclusion criteria, patients with severe BP, ie, SeDBP Ͼ115 mm Hg or SeSBP Ͼ200 mm Hg, will not be eligible to enter the study, as well as patients having a history of coronary heart disease within 6 months, or cerebrovascular disease within 12 months, or clinically significant arrhythmias, or heart failure evidenced by a left ventricular ejection fraction Ͻ40%.
Unpermitted concomitant medications will notably comprise of all other anti-hypertensive or vasodilator therapies, immunosuppressive agents, long-term treatment with psychotropic drug therapies, anti-convulsant agents, cimetidine, oral contraceptives, or steroid or adrenocorticotropic hormone therapy. Echocardiographic causes of error in LVMI measurement will be exclusions, ie, all marked regional wall motion abnormalities, asymetric LVH (ratio septum/posterior wall Ͼ1.5), septal subaortic hypertrophy, or ventricular dilatation defined as left ventricular end-diastolic dilatation Ͼ3.1 cm/m 2 .
Treatment regimens
Patients will start receiving single-blinded placebo capsules for at least 3 weeks (optional 4 weeks), and will have to show an 80-120% compliance assessed by capsule count (period A). Randomised, blinded treatment (period B) will be administered once daily in the morning between 6 am and 10 am for 12 months. Patients will be randomised baseline Ͻ10 mm Hg, will be able to be discontinued from the study and receive alternative therapy. At any time during the study, the finding of a SeSBP Ͼ200 mm Hg or SeDBP Ͼ115 mm Hg will necessitate the withdrawal of the subject from the study.
Echocardiographic methods
Echocardiograms will be centrally reviewed by the echocardiography laboratory from Henri-Mondor Hospital, Créteil, France. Echo video tapes will be blindly reanalysed by three independent reviewers, each of them being allocated video tapes at random. Echocardiography guidelines were provided to each study site, in writing as a manual of operations, and as a video tape prepared at the central echocardiography laboratory, describing the technical procedures for appropriate echocardiography measurements. The echocardiographer shall be the same for the same patient at each site. The echocardiography performance protocol requires the subject being in the left lateral decubitus position at end expiration. An M-mode recording under two-dimensional guidance will be performed in the parasternal projection perpendicular to the walls at the level of the tip of the anterior mitral leaflet. Other projections (eg, subcostal projections) may be considered when the other views are unsatisfactory. 38 All procedures will be followed according to the recommendations of the American Society of Echocardiography. 39, 40 Only subjects for whom technically satisfactory recordings are obtained will be eligible. A test echocardiography recording will be obtained at each site before the first screening echocardiogram is recorded on any study patient in order to assess the overall quality of the recordings. In order to avoid early dropouts, that may be as frequent as 47%, 9 the screening echocardiogram will be recorded prior to the administration of the first dose period. A study medication (placebo lead-in). The next echocardiogram will be obtained after randomisation but prior to the first dose of double-blind study medication. The two next echocardiograms will be recorded at 24 and 52 weeks, respectively. Therefore a total of four echocardiograms per patient completing the 52-week double-blind follow-up will be centrally reviewed.
All measurements and calculations will be based on the average of three consecutive cardiac cycles; in case of irregular rhythm, an average of five cycles will be used. All measurements will be made by standard procedures according to the Penn convention. 41 The calculation of LVM will be done using the Devereux formula:
where LVID d = left ventricular inner diameter diastole , IVS d = intraventricular septal thickness diastole , and PWT d = posterior left ventricular wall thickness diastole LVMI will be determined by the ratio LVM/body surface area.
Sample size justification
The primary purpose of this study is to compare the changes of LVMI from baseline to 52 weeks randomised therapy. With 132 subjects in each group at the week 52 analysis time point, there will be 90% power to detect differences between groups in change from baseline of approximately 8 g/m 2 .
Calculations assume that the standard deviation of change from baseline in LVMI is approximately 20 g/m 2 and that all statistical testing will be twosided with significance level = 0.05. The sample size has been increased to 180 subjects per group to allow for the possibility of 25% non-completion rate.
Statistical methods
Demographic data (eg, gender, race, age, weight and height), duration of hypertension, and baseline efficacy measures will be summarised by treatment regimen. All efficacy analyses including the primary analysis of the change in LVMI at week 52 will be performed with the available data from all randomised subjects. The primary efficacy variable is the change of LVMI from baseline to week 52 of doubleblind therapy. The mean changes from baseline between the treatment groups will be analysed using anlaysis of covariance with treatment as main factor and baseline measure as covariate.
In terms of safety analysis, all subjects who received at least one dose of study drug will be included in the analyses of safety. Evaluations of safety events such as adverse events and marked abnormalities will be summarised by treatment group, in the form of frequency distribution and tabulations of descriptive statistics. The number of subjects discontinuing the study prematurely will be summarised by treatment regimen and by reason(s) for premature discontinuation. Both treatment regimens will be compared for the incidence of oedema related to the study drug using Fisher's exact test.
